Abstracts tagged "autoimmune diseases"

Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Matt Makara, Casey Hogan
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
Abstract Number: 2601 • ACR Convergence 2025
Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
Antonios Psarras¹, Sinibaldo Arocha², Liezel Tamon², David Ahern², Md Yuzaiful Md Yusof³, Ed Vital⁴ and Alexander Clarke⁵, ¹University of Oxford, Oxford, England, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University of Leeds, Leeds, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by innate immune activation and autoantibodies against nucleic self-antigens. The metabolic state of immune cells is emerging as…
Abstract Number: 2500 • ACR Convergence 2025
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
Emily Glowienka¹, Sarah Nickolls², Kevin Coady¹, Eesha Kodi³, Ian Steinfield¹, Florence Wilson³, Alicia N. Pepper³, Svetlana I. Nihtyanova⁴, Roger A. Levy⁵ and Daniel Moldaver⁶, ¹Precision AQ, Boston, MA, ²GSK, Research & Development, Stevenage, United Kingdom, ³Precision AQ, Vancouver, BC, Canada, ⁴GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada
Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…
Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Guillaume Nardella¹, Gerber Gomez², Christian Fischer² and Claire Monat¹, ¹Inovie Labosud Provence, Specialized Autoimmunity Analyses, Marseille, France, ²Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…
Abstract Number: 2027 • ACR Convergence 2025
Development of a multi-disease panel for autoimmune diseases
Charlotta Preger, Maria Aspenberg, Metta Berenpas, Peter Nilsson and Elisa Pin, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…
Abstract Number: 1858 • ACR Convergence 2025
Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cells via a Clathrin Endocytosis Mechanism and Interact with their Intracellular Antigen.
Aurélien Chepy¹, Marie-Elise Martel¹, Solange Vivier¹, Meryem Tardivel², Antonino Bongiovanni², Marie Mistretta¹, Maxime Secq¹, Lucile Guilbert³, Eric HACHULLA⁴, Sylvain Dubucquoi⁵, David Launay¹ and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ - INFINITE - Institut de Recherche Translationnelle en Inflammation, Lille, France., Lille, France, ²Univ. Lille, BioImaging Center Lille-Nord de France (BICeL), Lille, France., Lille, France, ³CHU Lille, Institut d'Immunologie, Lille, France., Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France, ⁵Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France
Background/Purpose: Antinuclear autoantibodies (ANA) are robust biomarkers for the diagnosis and prognosis of systemic sclerosis (SSc), but their role in pathogenesis is still uncertain. Recent…
Abstract Number: 1696 • ACR Convergence 2025
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Vitor Aguiar¹, Marcella Franco¹, Nada Abdel Aziz¹, Daniela Fernandez-Salinas², Marcos Chinas¹, Mariasilvia Colantuoni², Qian Xiao¹, Nicolaj Hackert¹, Yifei Liao³, Rodrigo Cervantes-Diaz¹, Marc Todd¹, Brian Wauford¹, Alex Wactor¹, Vaishali Prahalad¹, Raquel Laza-Briviesca¹, Roxane Darbousset¹, Qiang Wang¹, Scott Jenks⁴, Kevin Cashman⁴, Esther Zumaquero⁴, Zhu Zhu¹, Junning Case³, Paloma Cejas⁵, Miguel Munoz-Gomez⁵, Hannah Ainsworth⁶, Miranda Marion⁷, Mehdi Benamar¹, Pui Lee⁸, Lauren Henderson⁹, Margaret Chang², Kevin Wei¹⁰, Henry Long⁵, Carl Langefeld¹¹, Benjamin Gewurz³, Ignacio Sanz⁴, Jeffrey Sparks¹², Esra Meidan¹³, Peter Nigrovic² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Boston, ²Boston Children's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Emory University, Atlanta, ⁵Dana Farber Cancer Institute, Boston, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest, Winston-Salem, ⁸Boston Children's Hospital, Newton, MA, ⁹Boston Children's Hospital, Watertown, MA, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Wake Forest University School of Medicine, Winston Salem, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Boston Children's Hospital, Somerville, MA
Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types…
Abstract Number: 1539 • ACR Convergence 2025
The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
Muhammad Usman Hashmi¹, Paramarajan Piranavan², Yasmeen Sufi³, Zaira Nasir⁴, Zainab Azhar⁵, Shamaem Tariq⁵, Hamas Ul Hudaibia⁵, IMRAN SAEED⁶, Aayet Zulfiqar⁵, Natasha Rasool² and Anum Faiz⁷, ¹Rahmah Academy of Research Excellence, Islamabad, Pakistan., Islamabad, Pakistan, ²University of Kentucky, Louisville, KY, ³Karachi Medical & Dental College, Karachi, Karachi, Pakistan, ⁴Rawalpindi Medical University,Rawalpindi, Pakistan., Islamabad, Pakistan, ⁵Rawalpindi Medical University,Rawalpindi, Pakistan., Rawalpindi, Pakistan, ⁶Nishtar Medical University,Multan, Pakistan., Multan, Pakistan, ⁷Jinnah Hospital Lahore, Pakistan, Lahore, Pakistan
Background/Purpose: Type I interferon (IFN) signaling is central to systemic lupus erythematosus (SLE) pathogenesis, and anifrolumab, a monoclonal antibody targeting the IFN-α receptor (IFNAR), has…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 1197 • ACR Convergence 2025
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
Bandana Jassal¹, Aishwarya Dhall¹, Mohammed Faruq², Danveer Bhadu¹, Uma Kumar¹ and Mehar Chand Sharma¹, ¹All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India, ²Institute of Genomics and Integrative Biology, New Delhi, Delhi, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune muscle disorders with complex genetic underpinnings. Most genetic studies have focused on limited populations. This study explores…
Abstract Number: 1100 • ACR Convergence 2025
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Gregory Challener¹, Chen Wang², David Gritsch², Ilana Usiskin³, Zandra E. Walton¹, Minna Kohler⁴, Hyon K. Choi⁵ and Jeffrey Sparks⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Harvard T.H. Chan School of Public Health, Boston, ³Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell…
Abstract Number: 0986 • ACR Convergence 2025
LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders.
Shuijun Hu¹, Fengxia Li¹, Aixia Liu¹, Hailin Wang¹, Xiaoxiao Liu¹, Jianming Sun¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Hui Yuwen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Inflammatory bowel disease (IBD) is a chronic, immune-mediated, inflammatory disease of the digestive tract. Several biological agents have greatly improved clinical course, remission, and…
Abstract Number: 0914 • ACR Convergence 2025
Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
Xiaohao Wu¹, Mengrui Zhang², Orr Sharpe³, V. Michael Holers⁴, Jane Buckner⁵, Gary Firestein⁵, Eddie James⁶, Kevin Deane⁷ and William H. Robinson⁸, ¹Stanford Uniersity, Stanford, ²Stanford University, Stanford, CA, ³Stanford University, Stanford, ⁴University of Colorado Anschutz Medical Campus, Aurora, ⁵Benaroya Research Institute, Seattle, ⁶Benaroya Research Institute, Benaroya Research Institute, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸Stanford University, Palo Alto, CA
Background/Purpose: The cellular and molecular mechanisms underlying the progression from anti-citrullinated protein antibody (ACPA) positivity to clinical rheumatoid arthritis (RA) remain poorly understood. Defining these…
Abstract Number: 0681 • ACR Convergence 2025
Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
Aïcha Kante¹, Sandra Mghaieth², bertrand Dunogue³, Alice berezne³, Cloé Comarmond¹, Marie-Pierre Revel², Guillaume Chassagnon², Luc Mouthon³ and Benjamin Chaigne³, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Radiology Department, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease that can manifest as widespread skin and visceral fibrosis, potentially affecting major organs including the heart.…
Abstract Number: 0860 • ACR Convergence 2025
Activated protein C resistance and protein C antibodies in the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository
Maria Efthymiou¹, Ibrahim Tohidi-Esfahani², Veronica Venturelli¹, Maria Tektonidou³, Vittorio Pengo⁴, Diana Parades-Ruiz⁵, Ware Branch⁶, Maria Gerosa⁷, Cecilia Nalli⁸, Esther Rodriguez Almaraz⁹, Michelle Petri¹⁰, Ricard Cervera¹¹, Olga Amengual¹², Danieli Andrade¹³, Rohan Willis¹⁴, Maria Laura Bertolaccini¹⁵, Doruk Erkan¹⁶ and Hannah Cohen¹⁷, ¹University College London, London, United Kingdom, ²University of Sydney, Syndey, Australia, Sydney, Australia, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵Biobizkaia Health Research Institute, Barakaldo, Spain, Barakaldo, Spain, ⁶University of Utah Health Sciences Center, Salt Lake City, UT, ⁷University of Milan, Milano, Italy, ⁸ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁹Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Hospital Clinic Barcelona, Barcelona, Spain, ¹²Hokkaido University Graduate School of Medicine, Sapporo, Japan, Sapporo, Japan, ¹³University of Sao Paulo, São Paulo, São Paulo, Brazil, ¹⁴University of Texas Medical Branch, Galveston, TX, ¹⁵King's College London, London, United Kingdom, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Dysregulation in the protein C anticoagulant pathway, more specifically acquired resistance to activated protein C (APCr) and antibodies against protein C (anti-PC), has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].